14.11.2022 - Continued Progress in Pepinemab Oncology and Neurology Clinical ProgramsPromising initial responses in Phase 1b/2 open-label KEYNOTE B84 study of pepinemab with KEYTRUDA in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patient .
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022 uniQure N.V. , a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its. | September 6, 2022
LEXINGTON, Mass. and AMSTERDAM, Sept. 06, 2022N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation